Adaptimmune raises $104M series A

T cell therapy company Adaptimmune Ltd. (Abingdon, U.K.) raised $104 million in an untranched series A round led by New Enterprise Associates. Other new investors included OrbiMed Advisors; Wellington Management; Fidelity Biosciences; Foresite Capital; Ridgeback Capital; Novo A/S; QVT; Rock Springs Capital; venBio Select; and Merlin Nexus. The University of Oxford and other existing investors also participated.

NEA's David Mott and Ali Behbahani, and OrbiMed's Peter Thompson joined the biotech's board. ...